Rudick R A, Bidlack J M, Knutson D W
Arch Neurol. 1985 Sep;42(9):856-8. doi: 10.1001/archneur.1985.04060080034012.
We used a sensitive C1q-binding assay to measure levels of soluble immune complexes in 182 samples of cerebrospinal fluid (CSF) from control patients and patients with multiple sclerosis (MS). Soluble immune complexes in CSF were detected in 16% of patients with progressive MS, 38% of patients with exacerbating-remitting MS, 55% of patients with infectious or inflammatory diseases, 3% of patients with noninflammatory neurologic disorders, and in 0% of control patients with back pain. No correlations were found between the results of the C1q-binding assay and abnormalities of other CSF parameters. These included an elevated level of myelin basic protein, pleocytosis, oligoclonal bands, or an increased IgG level. Because of the lack of correlation to laboratory indexes of disease activity and the nonspecificity of a positive test, the C1q-binding assay seems to have little clinical usefulness in the diagnosis or management of patients with MS.
我们采用一种灵敏的C1q结合试验来检测182份来自对照患者及多发性硬化症（MS）患者的脑脊液（CSF）样本中的可溶性免疫复合物水平。在进行性MS患者中，16%的患者脑脊液中检测到可溶性免疫复合物；复发缓解型MS患者中这一比例为38%；感染性或炎症性疾病患者中为55%；非炎症性神经疾病患者中为3%；而因背痛前来就诊的对照患者中未检测到可溶性免疫复合物（比例为0%）。C1q结合试验结果与其他脑脊液参数异常之间未发现相关性。这些参数包括髓鞘碱性蛋白水平升高、细胞增多、寡克隆带或IgG水平升高。由于与疾病活动的实验室指标缺乏相关性且阳性检测结果不具有特异性，C1q结合试验在MS患者的诊断或管理中似乎临床实用性不大。
